Evidence map›Paper›PMID 34373716›Full record

ArticleExperimental and therapeutic medicine2021

Weighted gene co-expression network analysis of the association between upregulated AMD1, EN1 and VGLL1 and the progression and poor prognosis of breast cancer.

Lijie Yang, Xuanfei Li, Yixing Luo, Tiecheng Yang, Huaqiao Wang, Liwen Shi, Maohui Feng, Wei Xie

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lijie YangDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Xuanfei LiDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Yixing LuoDepartment of Emergency, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Tiecheng YangDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Huaqiao WangDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Liwen ShiDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Maohui FengDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Wei XieDepartment of Gastrointestinal Surgery, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Province, Key Laboratory of Tumor Biological Behavior of Hubei, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.
Zhongnan Hospital of Wuhan University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most prevalent malignancy among females, but the molecular mechanisms involved in its pathogenesis and progression have remained to be fully elucidated. The aim of the present study was to identify novel potential therapeutic targets for breast cancer. The dataset GSE76275 was downloaded from the Gene Expression Omnibus database and weighted gene co-expression network analysis (WGCNA) was performed to identify hub genes. Furthermore, the dataset GSE25055, containing gene expression data and clinical information, was downloaded to validate the expression and survival association of these hub genes. In addition, the datasets GSE25065 and GSE42568 were used to validate the association between hub gene expression levels and clinical features. Immunohistochemistry (IHC), reverse transcription-quantitative PCR, as well as proliferation, migration, invasion and apoptosis assays, were used to verify gene expression and function. A total of 4,052 genes were selected for WGCNA and 18 modules were established; the red module was identified as the key module, as it had a strong positive correlation with the tumor grade. Survival analyses of hub genes [S-adenosylmethionine decarboxylase proenzyme (AMD1), homeobox protein engrailed-1 (EN1) and vestigial-like protein (VGLL1)] indicated that higher levels of gene expression were associated with poor prognosis of patients with breast cancer. This association was based on survival analysis of GSE25055 using the Kaplan-Meier plotter tool. Expression validation revealed that the upregulation of hub genes was associated with advanced tumor grade and malignant molecular subtype (basal-like). IHC results from the Human Protein Atlas also demonstrated that protein expression levels of the hub genes were higher in tumor tissues compared with those in adjacent normal tissues. Furthermore, the expression levels of AMD1, EN1 and VGLL1 were strongly correlated with each other. These results demonstrated that AMD1 is highly expressed in breast cancer tissues and cells and AMD1 knockdown decreased the proliferation and metastatic potential, while increasing apoptosis of breast cancer cells. These results suggested that AMD1, EN1 and VGLL1 are likely to contribute to breast cancer progression and unfavorable prognosis.

Indexed as

biomarkerbreast cancerGene Expression Omnibushomeobox protein engrailed-1S-adenosylmethionine decarboxylase proenzymevestigial-like protein 1weighted gene co-expression network analysis

Identifiers

PMID34373716
PMCPMC8343771
OpenAlexW3185964180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.